- Home
- LIXT vs APM Comparison
LIXT vs APM Comparison
Compare LIXT & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- APM
- Stock Information
- Founded
- LIXT 2005
- APM 2010
- Country
- LIXT United States
- APM United Kingdom
- Employees
- LIXT N/A
- APM N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- APM Health Care
- Exchange
- LIXT Nasdaq
- APM Nasdaq
- Market Cap
- LIXT 4.1M
- APM 4.1M
- IPO Year
- LIXT N/A
- APM 2018
- Fundamental
- Price
- LIXT $2.33
- APM $1.15
- Analyst Decision
- LIXT
- APM
- Analyst Count
- LIXT 0
- APM 0
- Target Price
- LIXT N/A
- APM N/A
- AVG Volume (30 Days)
- LIXT 18.9K
- APM 7.0M
- Earning Date
- LIXT 11-12-2024
- APM 12-20-2024
- Dividend Yield
- LIXT N/A
- APM N/A
- EPS Growth
- LIXT N/A
- APM N/A
- EPS
- LIXT N/A
- APM 0.00
- Revenue
- LIXT N/A
- APM N/A
- Revenue This Year
- LIXT N/A
- APM $157,729.10
- Revenue Next Year
- LIXT N/A
- APM N/A
- P/E Ratio
- LIXT N/A
- APM $345.64
- Revenue Growth
- LIXT N/A
- APM N/A
- 52 Week Low
- LIXT $1.31
- APM $0.46
- 52 Week High
- LIXT $4.40
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- LIXT 54.46
- APM 47.12
- Support Level
- LIXT $2.25
- APM $1.21
- Resistance Level
- LIXT $2.68
- APM $1.30
- Average True Range (ATR)
- LIXT 0.23
- APM 0.75
- MACD
- LIXT 0.01
- APM -0.06
- Stochastic Oscillator
- LIXT 53.90
- APM 4.58
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.